Canine Pulmonary Hypertension: Classification and Care

Bottom line

Canine pulmonary hypertension (PH) is a hemodynamic state with multiple possible causes. ACVIM recommends assessing its probability and identifying contributing disease before selecting treatment. [1] A pulmonary vasodilator prescription should follow that assessment, with a defined clinical objective and surveillance plan.

Establish probability without confusing an estimate with a diagnosis

Echocardiography estimates the probability of PH rather than providing definitive catheter-based confirmation. Interpret tricuspid regurgitation velocity alongside other cardiac findings and the clinical presentation. [1]

Ask the echocardiographer to state confidence, image quality, the supporting findings, and important competing interpretations. Preserve the actual study rather than carrying forward only a pressure estimate in a referral summary. Label an uncertain result as uncertain; a precise-looking number does not remove uncertainty about acquisition or interpretation.

Record the presentation that prompted investigation: exercise-associated collapse, respiratory limitation, right-sided congestion, or another concern. Specify which findings are observed and which are attributed to PH. If the examination and imaging disagree, resolve the discrepancy before treating an isolated estimate as the entire problem.

Classify the contributors before selecting a drug

The consensus separates pulmonary arterial disease from PH associated with left-heart disease, respiratory disease or hypoxia, thromboembolic disease, parasites, and multifactorial mechanisms. More than one category can coexist. [1]

Use a problem list that names each supported contributor and the evidence still needed. A small dog with valvular disease and inspiratory noise should not have every limitation assigned to the murmur. The laryngeal paralysis pathway addresses an independently supported upper-airway question; the pimobendan and MMVD reference addresses valvular staging and its treatment.

For each proposed investigation, state what result would change treatment. Distinguish an unresolved differential from a confirmed contributor. This is particularly useful when a referral contains several plausible explanations for cough or collapse but no documented connection between them.

Apply sildenafil trial results to the endpoint actually studied

A small prospective randomized, double-blind, placebo-controlled crossover trial evaluated sildenafil in dogs with echocardiographic evidence of pulmonary arterial hypertension. Estimated pressure was lower than baseline during sildenafil treatment, but was not significantly lower than during placebo treatment. Exercise capacity and quality-of-life scores were better with sildenafil than placebo. [2]

This distinction matters: the pressure comparison and functional comparison do not support identical claims. The short-term trial supports a potential clinical benefit, not proof of a survival advantage or a universally improved pressure measurement. [2] Avoid describing a before-versus-after change as though it were a statistically significant drug-versus-placebo result.

Define the treatment goal before initiation. Choose an outcome that reflects the patient's actual limitation and record the baseline in a way that can be repeated. Keep caregiver-reported function separate from the imaging estimate so one favorable result does not conceal deterioration in another domain.

Interpret observational improvement cautiously

An early retrospective series associated sildenafil treatment with improved signs and lower estimated pressures in reevaluated dogs. Underlying disease varied, concurrent medication was common, and not every dog underwent pressure reassessment. [3]

Those observations support clinical feasibility but cannot isolate sildenafil's effect from treatment of concurrent disease or selection of patients returning for reexamination. The reported survival experience has no untreated comparator. [3] Do not promise an individual prognosis from that series or treat its historical dose distribution as a prescribing standard.

Verify local authorization, formulation, intended regimen, interactions, contraindications, and prescribing requirements before use. This hub deliberately omits a universal dose because treatment selection is the decision being addressed.

Apply the left-heart and venous-obstruction cautions

For PH associated with left-heart disease, ACVIM requires exclusion of acute or decompensated left-heart failure with pulmonary edema before a phosphodiesterase-5 inhibitor (PDE5i) is considered. Selected dogs with compensated left-heart failure, a high probability of PH, and cardiogenic ascites or otherwise unexplained exertional syncope may be candidates for adjunctive treatment. [1]

For suspected pulmonary veno-occlusive disease or pulmonary capillary hemangiomatosis, the panel recommends hospital initiation with close edema surveillance and immediate withdrawal if acute pulmonary edema develops. The concern draws on human experience; comparable veterinary evidence is insufficient. [1]

These distinctions should appear in the treatment decision itself. State whether the dog currently has edema, what supports the proposed PH mechanism, and why vasodilation is being considered. Revisit the mechanism when clinical deterioration follows treatment rather than automatically increasing the same medication.

Frequently Asked Questions

Does echocardiography definitively establish pulmonary hypertension?

No. ACVIM treats echocardiography as a probability assessment; definitive pressure measurement requires right-heart catheterization. [1]

Is pulmonary hypertension always primary pulmonary arterial disease?

No. Left-heart, respiratory, thromboembolic, parasitic and multifactorial disorders can contribute. [1]

Should every asymptomatic dog with an abnormal Doppler result receive sildenafil?

No. The consensus does not advocate PH-specific treatment without compatible clinical signs or findings. [1]

Did the crossover trial show lower pressure than placebo?

No significant pressure difference versus placebo was detected, although pressure fell from baseline during sildenafil treatment. [2]

What improved compared with placebo in that trial?

Exercise capacity and quality-of-life scores improved during sildenafil treatment. [2]

Does the early retrospective series establish a survival benefit?

No. It lacked an untreated comparison group and concurrent treatments were common. [3]

Why reassess breathing after starting a pulmonary vasodilator?

Pulmonary edema is a recognized concern in selected settings, including left-heart disease, and requires clinical surveillance. [1]